The downgrade from Buy to Hold by a major analyst firm like Jefferies, accompanied by a drastic reduction in the price target, suggests a significant change in the firm's outlook on Reneo Pharmaceuticals. This is likely to be interpreted negatively by the market, potentially leading to a decrease in investor confidence and a short-term decline in the stock price.